Publication related to RSI or an RSI staff member

Lung Volume Recruitment and Quality of Life in Duchenne Muscular Dystrophy: Secondary Analysis of the STEADFAST Randomized Controlled Trial.

BACKGROUND: Lung volume recruitment (LVR) is prescribed for children with Duchenne muscular dystrophy (DMD), to maintain chest wall compliance and assist airway clearance. We aimed to determine if twice-daily LVR compared to standard treatment in children with DMD improved health related quality of life (HRQOL) over 2 years. METHODS: A multicentre, assessor-blinded randomized controlled trial was conducted, including boys 6-16 years with DMD with forced vital capacity >30% predicted to undergo conventional treatment or conventional treatment and manual LVR twice-daily for two years. Outcome was HRQOL measured by two validated instruments (PedsQL, DMD PedsQL) every 6 months. RESULTS: Sixty-two boys (33 LVR group and 29 controls), median (IQR) age 11.4 (9.4,13.4) years completed the study. Median (IQR) baseline HRQOL assessed by parent/caregiver PedsQL was 58.0 (41.9, 67.0) and 55.2 (47.8, 63.5) for the LVR and control groups. HRQOL trajectories were stable over the 2-year study period except parent communication, which improved. No statistically significant interactions were detected between visit and treatment group for any PedsQL outcomes. DMD PedsQL communication scores in the LVR group showed more positive change compared to controls. Treatment scores in the LVR group showed less positive change over time compared to controls; however, after correcting for multiple testing, were no longer significant. Respiratory symptom rate did not differ between groups and was not associated with any HRQOL outcome. CONCLUSION: There was no difference in HRQOL between the LVR and control groups after two years. The burden of LVR did not appear to adversely affect HRQOL.

Authors

  • Tsampalieros, Anne, Tsampalieros A, CHEO Research Institute, Ottawa, Ontario, Canada.

  • McKim, Doug, McKim D, Department of Medicine in Ottawa, Ottawa, Ontario, Canada.; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; Ottawa Hospital Rehabilitation Centre, Ottawa, Ontario, Canada.

  • Barrowman, Nick, Barrowman N, CHEO Research Institute, Clinical Research Unit, Ottawa, Ontario, Canada.; University of Ottawa Faculty of Medicine, Faculty of Medicine, Ottawa, Ontario, Canada.

  • Bijelic, Vid, Bijelic V, CHEO Research Institute, Ottawa, Ontario, Canada.

  • Mah, Jean K, Mah JK, Alberta Children's Hospital, Calgary, Alberta, Canada.; University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada.

  • McMillan, Hugh J, McMillan HJ, Children's Hospital of Eastern Ontario, Pediatrics, Ottawa, Ontario, Canada.; CHEO Research Institute, Ottawa, Ontario, Canada.; University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.

  • Campbell, Craig, Campbell C, University of Western Ontario, London, Ontario, Canada.; London Health Sciences Centre Children's Hospital, Pediatrics, London, Ontario, Canada.

  • Momoli, Franco, Momoli F, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.; University of Ottawa, School of Epidemiology and Public Health, Ottawa, Ontario, Canada.

  • Blinder, Henrietta, Blinder H, CHEO Research Institute, Ottawa, Ontario, Canada.

  • McAdam, Laura, McAdam L, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada.; University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.

  • Nguyen, The Thanh Diem, Nguyen TTD, Centre Hospitalier Universitaire Sainte-Justine, Department of Respiratory Medicine, Montreal, Quebec, Canada.

  • Tarnopolsky, Mark, Tarnopolsky M, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.

  • Wensley, David F, Wensley DF, BC Children's Hospital, Vancouver, British Columbia, Canada.; The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.

  • Zielinski, David, Zielinski D, Montreal Children's Hospital, Respiratory Medicine, Montreal, Quebec, Canada.; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

  • Katz, Sherri L, Katz SL, CHEO Research Institute, Ottawa, Ontario, Canada.; University of Ottawa Faculty of Medicine, Pediatrics, Ottawa, Ontario, Canada.; Children's Hospital of Eastern Ontario, Pediatrics, Division of Pediatric Respirology, Ottawa, Ontario, Canada; skatz@cheo.on.ca.

YEAR OF PUBLICATION: 2025
SOURCE: Ann Am Thorac Soc. 2025 Apr 4. doi: 10.1513/AnnalsATS.202404-360OC.
JOURNAL TITLE ABBREVIATION: Ann Am Thorac Soc
JOURNAL TITLE: Annals of the American Thoracic Society
ISSN: 2325-6621 (Electronic) 2325-6621 (Linking)
PLACE OF PUBLICATION: United States
ABSTRACT:
BACKGROUND: Lung volume recruitment (LVR) is prescribed for children with Duchenne muscular dystrophy (DMD), to maintain chest wall compliance and assist airway clearance. We aimed to determine if twice-daily LVR compared to standard treatment in children with DMD improved health related quality of life (HRQOL) over 2 years. METHODS: A multicentre, assessor-blinded randomized controlled trial was conducted, including boys 6-16 years with DMD with forced vital capacity >30% predicted to undergo conventional treatment or conventional treatment and manual LVR twice-daily for two years. Outcome was HRQOL measured by two validated instruments (PedsQL, DMD PedsQL) every 6 months. RESULTS: Sixty-two boys (33 LVR group and 29 controls), median (IQR) age 11.4 (9.4,13.4) years completed the study. Median (IQR) baseline HRQOL assessed by parent/caregiver PedsQL was 58.0 (41.9, 67.0) and 55.2 (47.8, 63.5) for the LVR and control groups. HRQOL trajectories were stable over the 2-year study period except parent communication, which improved. No statistically significant interactions were detected between visit and treatment group for any PedsQL outcomes. DMD PedsQL communication scores in the LVR group showed more positive change compared to controls. Treatment scores in the LVR group showed less positive change over time compared to controls; however, after correcting for multiple testing, were no longer significant. Respiratory symptom rate did not differ between groups and was not associated with any HRQOL outcome. CONCLUSION: There was no difference in HRQOL between the LVR and control groups after two years. The burden of LVR did not appear to adversely affect HRQOL.
LANGUAGE: eng
DATE OF PUBLICATION: 2025 Apr 4
DATE OF ELECTRONIC PUBLICATION: 20250404
DATE REVISED: 20250404
MESH DATE: 2025/04/05 15:58
EDAT: 2025/04/05 15:58
STATUS: Publisher
PUBLICATION STATUS: aheadofprint
LOCATION IDENTIFIER: 10.1513/AnnalsATS.202404-360OC [doi]
OWNER: NLM

Related RSI Experts

Franco Momoli

Vice-President Chemical and Product Safety

Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...
Read More about Franco Momoli